-
‘Capacity constraints’ to limit menopause drug supply until 2022
Australian pharmacists have been given the green light to substitute a key menopause treatment with other products due to major global supply chain disruption expected to last until May 2022.
The Therapeutic Goods Administration (TGA) has declared Progynova as a scarce medicine and allowed pharmacies to give patients with a prescription for the product two alternative drugs, Estrofem or Zumenon, instead.
Progynova is a hormone replacement therapy medicine designed for short-term use for helping relieve symptoms associated with menopause including hot flushes, sleep disturbances and depressive moods. It can also be prescribed to transgender people.
The drug’s local sponsor, Bayer Australia and New Zealand, said the shortage was due to limits on manufacturing capacity.
“Bayer confirms that there is a temporary shortage of its hormonal products caused by capacity constraints in Bayer’s global supply network for hormonal products and has an impact on a number of countries,” a spokeswoman said.
“Due to the specific nature of the hormonal product formulations and packaging, an increase in production or moving significant volumes to other manufacturing sites is not feasible.”
The company informed the TGA earlier this year that it expected the shortages to remain until May 2022. Bayer is “pursuing resupply with urgency”, it said.
The TGA told doctors last week to be alert to the current shortages. “Consider prescribing available estradiol-only tablets such as Estrofem or Zumenon,” the regulator said.
Read the full article here https://www.smh.com.au/business/consumer-affairs/capacity-constraints-to-limit-menopause-drug-supply-until-2022-20210816-p58j2z.html
-
This discussion was modified 3 years, 5 months ago by
Adrian.
-
This discussion was modified 3 years, 5 months ago by
-
0 Replies
Sorry, there were no replies found.